The Nordic Track for financing biotechs

A pharma history and healthy risk appetite has given Scandinavia a vibrant translational environment and broad interest in investing in life sciences. But easy money isn’t always the best money for building a globally competitive biotech company.

Like much of Europe, Scandinavia has a strong foundation of basic research that consistently generates innovation, and thanks to the Novo family of companies and foundations in Denmark, as well as the legacy of Astra AB and Pharmacia in Sweden, the region has a broad base of experience in how to translate those discoveries into new companies...